US EditionRakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding
- Rakuten Medical announced on June 4, 2025, that its RM-0256 photoimmunotherapy targeting PD-L1 received AMED funding in Japan.
- The funding follows the urgent need for new treatments, as RM-0256 targets malignant epithelial tumors resistant to current therapies.
- RM-0256 combines an anti-PD-L1 antibody and IRDye 700DX, a light-activated dye, to induce local and systemic antitumor effects via photoimmunotherapy.
- Preclinical studies indicate RM-0256 activates a triple mechanism of action and may apply to multiple cancers, affecting roughly 22,000 patients annually in Japan.
- AMED funding will support RM-0256's clinical development targeting unresectable and recurrent malignant epithelial tumors, aiming to expand treatment options.
27 Articles
27 Articles
Aspen Daily News
Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding
AMED grant to support the clinical development of RM-0256 photoimmunotherapy for targeting malignant epithelial tumorsTargeting PD-L1, pre-clinical observations indicate RM-0256 harnesses a triple mechanism of action, with potential applications across a broad range of solid tumors, including melanoma, ocular melanoma,…
MobiFone taps Rakuten Symphony for open RAN pilot
Vietnam operator MobiFone lined up Rakuten Symphony to support its rollout of a nationwide 4G and 5G open RAN network, as the Japanese software vendor continues to expand its global footprint. The pair, which signed an agreement to run a pilot project, noted in a joint release the deployment will make the operator one of the first in Southeast Asia to use open RAN. As part of the deal, Rakuten Symphony will supply its open RAN kit and work with …
Coverage Details
Bias Distribution
- 81% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
